Response Predictive Markers and Synergistic Agents for Drug Repositioning of Statins in Ovarian Cancer

Yusuke Kobayashi, Takashi Takeda, Haruko Kunitomi, Fumiko Chiwaki, Masayuki Komatsu, Shimpei Nagai, Yuya Nogami, Kosuke Tsuji, Kenta Masuda, Hideaki Ogiwara, Hiroki Sasaki, Kouji Banno, Daisuke Aoki

研究成果: Article査読

抄録

In the field of drug repurposing, the use of statins for treating dyslipidemia is considered promising in ovarian cancer treatment based on epidemiological studies and basic research findings. Biomarkers should be established to identify patients who will respond to statin treatment to achieve clinical application. In the present study, we demonstrated that statins have a multifaceted mode of action in ovarian cancer and involve pathways other than protein prenylation. To identify biomarkers that predict the response to statins, we subjected ovarian cancer cells to microarray analysis and calculated Pearson’s correlation coefficients between gene expression and cell survival after statin treatment. The results showed that VDAC1 and LDLRAP1 were positively and negatively correlated with the response to statins, respectively. Histoculture drug response assays revealed that statins were effective in clinical samples. We also confirmed the synergistic effects of statins with paclitaxel and panobinostat and determined that statins are hematologically safe to administer to statin-treated mice. Future clinical trials based on the expression of the biomarkers identified in this study for repurposing statins for ovarian cancer treatment are warranted.

本文言語English
論文番号124
ジャーナルPharmaceuticals
15
2
DOI
出版ステータスPublished - 2022 2月

ASJC Scopus subject areas

  • 分子医療
  • 薬科学
  • 創薬

フィンガープリント

「Response Predictive Markers and Synergistic Agents for Drug Repositioning of Statins in Ovarian Cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル